Denied Dupixent? You Still Have Options.
Dupixent (dupilumab) is a biologic that blocks two key inflammatory signals and is approved for atopic dermatitis (eczema), severe asthma, chronic sinusitis with nasal polyps, eosinophilic esophagitis, and other conditions. Denials are extremely common because prior authorization requirements are strict, and most plans require documented failure of multiple older treatments before they'll approve Dupixent. Step therapy is the rule, not the exception — even when your doctor believes you need Dupixent now.
Option 1: Appeal Your Denial
The most effective appeals document your treatment history in detail: every topical steroid, antihistamine, older biologic, or other therapy you've tried and why it wasn't sufficient. Your dermatologist, allergist, or pulmonologist can frame that history in clinical terms that speak directly to the plan's criteria. Ellen can help you draft your appeal letter.
Option 2: Explore Clinical Trials
Dupilumab and related IL-4/IL-13 pathway inhibitors are among the most actively researched therapies in allergy and immunology. Trials study Dupixent across its approved indications and in new areas. Participating in a trial may provide access to Dupixent or a next-generation similar therapy at no cost. Search ClinicalTrials.gov for "dupilumab" or your specific condition to see current opportunities.
Option 3: Patient Assistance Programs
Sanofi and Regeneron, who co-market Dupixent, offer the Dupixent MyWay program, which includes copay assistance and access support for eligible individuals. The National Eczema Association (nationaleczema.org) and the Asthma and Allergy Foundation of America (aafa.org) also provide resources for people navigating Dupixent access challenges.
For a complete guide to Dupixent financial assistance — including copay cards, free drug programs, and independent foundations — see our financial assistance page for Dupixent.
Ellen can help you figure out your next step. Start with Ellen →
Frequently Asked Questions
Why was Dupixent denied?
Dupixent is most frequently denied because of step therapy requirements — your insurer typically wants documented evidence that you've tried and failed conventional treatments (topical steroids, systemic immunosuppressants, older medications) before approving a biologic. Missing prior authorization, diagnosis documentation issues, or the requested use being outside your plan's specific criteria are other common reasons. The denial letter will tell you exactly what the plan says is missing.
Can I get Dupixent through a clinical trial?
Yes, this is a realistic path for some people. Dupilumab is studied in ongoing trials for its approved conditions and emerging uses, and participants may receive the medication at no charge. There are also trials studying next-generation biologics in the same IL-4/IL-13 pathway that may be relevant for your condition. Talk to your doctor about whether you might qualify, and search ClinicalTrials.gov for currently enrolling studies.
How long does a Dupixent appeal take?
Standard internal appeals are decided within 30 days for non-urgent cases, and within 72 hours when your doctor certifies the situation is medically urgent. If your internal appeal is denied, you can request an independent external review, which generally resolves within 45 days. Some people find they need to go through multiple rounds — keep detailed records of everything you submit and every response you receive. Talk to your doctor before making any decisions about your treatment.